---
title: "SINO BIOPHARM will submit a market application for a lung cancer treatment drug in the near future"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/223371831.md"
description: "SINO BIOPHARM will soon submit a marketing application for Bemarituzumab injection in combination with chemotherapy, which is used for the treatment of advanced squamous non-small cell lung cancer. Phase III studies have shown that the primary endpoint of progression-free survival (PFS) has reached the predefined efficacy threshold. This application marks the sixth indication for Bemarituzumab and the thirteenth indication for Anlotinib, and it is expected to provide new treatment options for patients. The group also plans to announce detailed research data at an international academic conference"
datetime: "2024-12-27T00:25:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/223371831.md)
  - [en](https://longbridge.com/en/news/223371831.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/223371831.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/223371831.md) | [English](https://longbridge.com/en/news/223371831.md)


# SINO BIOPHARM will submit a market application for a lung cancer treatment drug in the near future

SINO BIOPHARM (01177.HK) announced that its self-developed Class 1 innovative drug Bemarituzumab injection combined with chemotherapy followed by Anlotinib hydrochloride capsules compared to Toripalimab injection combined with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) has completed the pre-specified interim analysis of the Phase III study (TQB2450-III-12), and the Independent Data Monitoring Committee (IDMC) determined that the primary endpoint of progression-free survival (PFS) has reached the pre-specified efficacy boundary.

The group has communicated with the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) regarding the marketing application for this indication and has obtained written consent from the CDE to submit the marketing application for Bemarituzumab injection and Anlotinib hydrochloride capsules for this new first-line indication. The group will submit the marketing application in the near future.

The combination of Bemarituzumab with chemotherapy followed by Anlotinib for the first-line treatment of advanced sq-NSCLC is the 13th indication for which Anlotinib is about to be submitted for marketing and the 6th indication for which Bemarituzumab is about to be submitted for marketing, expected to bring new clinical treatment options for sq-NSCLC patients.

In addition, the group stated that the TQB2450-III-12 study is the world's first Phase III clinical study that has achieved positive results comparing immunotherapy (PD-1) combined with chemotherapy for the first-line treatment of sq-NSCLC. The group plans to announce detailed research data at an upcoming international authoritative academic conference

### 相關股票

- [SBP GROUP (01177.HK)](https://longbridge.com/zh-HK/quote/01177.HK.md)

## 相關資訊與研究

- [Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update](https://longbridge.com/zh-HK/news/280904911.md)
- [Styland Subsidiary Commits US$3.4 Million to Alpha Perpetual Income Fund](https://longbridge.com/zh-HK/news/281380835.md)
- [Hing Yip Unit to Buy to Lease Back Assets](https://longbridge.com/zh-HK/news/281507408.md)
- [14:09 ETSeena Magowitz Foundation and Top Chef Team Partner on YouTube Pancreatic Cancer Cooking Series](https://longbridge.com/zh-HK/news/281410037.md)
- [In pursuit of profit, India Inc slows R&D as innovation takes back seat](https://longbridge.com/zh-HK/news/281098039.md)